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Abstract 
Introduction: Hürthle cell carcinoma (HCC) is a rare tumor that tends to metastasize to the 
lymph nodes. Some studies have correlated size of Hürthle cell tumors with the risk of ma-
lignancy. Whether the size of HCC correlates with the risk of lymph node (LN) metastases, to 
our knowledge has not been addressed.  
Methods: A retrospective analysis was performed on all patients diagnosed with HCC on 
final pathology between 1997 and 2008. The tumor size and lymph node status was obtained 
for each patient. The data were analyzed utilizing Student’s t-test and the Fisher's exact test to 
calculate the two-tailed p-value. 
Results: Out of 39 patients diagnosed with HCC 3(8%) had LN metastases; 1 had ipsilateral 
central LN metastasis and 2 had ipsilateral central and lateral LN metastasis. LN dissection 
was performed in patients with known metastasis (2 were evident on preoperative ultrasound 
and 1 intraoperatively). Patients with LN metastasis were older than those without (mean age: 
86.7 and 56.4 years, respectively), had larger tumors (mean size: 6 and 4 cm) and were 
commonly male (2 of 3). No tumor < 5cm presented with lymph node involvement (3/15 with 
>5cm cancer had node metastasis, 0/24 with <5cm cancer had node metastasis).  
Conclusions: Similar to what has been found in patients with papillary thyroid cancer, older 
male patients with Hürthle cell carcinomas greater than 5cm are more likely to have lymph 
node metastasis. Our data suggest that these patients may benefit from a prophylactic ipsi-
lateral central neck dissection at the time of their initial operation.  
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Introduction 
Hürthle cell carcinoma (HCC) is a distinct and 
rare subtype of well-differentiated thyroid cancers. 
The aggressive nature of HCC stems from the higher 
propensity for multifocality, lymph node (LN) me-
tastasis and distant metastasis compared to the other 
types of well-differentiated thyroid cancer. The limi-
tation, however, is the difficulty in obtaining an ac-
curate diagnosis preoperatively. Unlike the more 
common papillary thyroid cancer, HCC cannot be 
diagnosed on fine-needle aspiration (FNA). Rather, 
FNA typically yields the diagnosis of Hürthle cell 
neoplasm. The definition of a neoplasm differs in the 
literature, with some recommending the presence of 
greater than 50% Hürthle cells 1, 2, while others use 
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greater than 75% 3, 4 as the cutoff. Regardless of the 
percent cellularity, the presence of capsular and/or 
vascular invasion is required to make the diagnosis of 
HCC on histopathology.  
  Attempts have been made to identify clinical 
parameters that can accurately predict the malignant 
potential of Hürthle cell neoplasms.2 However, tumor 
size has been shown to be predictive of malignancy in 
several studies.1, 5-7 Our group previously demon-
strated that the risk of malignancy in a Hürthle cell 
neoplasm was 55% for tumors > 4 cm and only 13% 
for tumors ≤ 4 cm.5 This finding is corroborated in 
other studies that found that between 44%8 and 65%1 
of neoplasms > 4 cm were malignant.  Determining 
the malignant potential of Hürthle cell neoplasm is 
important because it can change the initial surgical 
approach from a lobectomy to a total thyroidectomy. 
Similarly, determining the risk of LN metastasis can 
also help in operative planning. The aim of this study 
was to determine if tumor size correlated with LN 
metastasis in patients diagnosed with HCC. 
Materials and Methods 
We retrospectively analyzed the records of all 
patients who underwent a thyroid operation at the 
University of California, San Francisco from February 
1997 to September 2008. Patients who were diagnosed 
with Hürthle cell carcinoma on final pathology were 
used for analysis. Patient demographics, preoperative 
imaging results, intraoperative findings, and post-
operative outcome data were collected. The institu-
tional review board at the University of California, 
San Francisco, approved the study. 
 A fine needle aspiration (FNA) of suspicious 
thyroid nodules and/or lymph nodes was performed 
for diagnosis. An ultrasound (US) of the neck was 
performed to evaluate the thyroid gland and lymph 
node basins. The type of surgical procedure was dic-
tated by clinical parameters: A thyroid lobectomy was 
performed on patients with a thyroid neoplasm and 
no contralateral thyroid nodules or suspicious cervical 
lymphadenopathy, with a completion thyroid lo-
bectomy if final pathology revealed HCC; a total 
thyroidectomy was performed on patients with a 
thyroid neoplasm and contralateral thyroid nodules 
or suspicious cervical lymphadenopathy; a total thy-
roidectomy and cervical lymph node dissection (cen-
tral and/or lateral) was performed when suspicious 
lymphadenopathy was found preoperatively on ul-
trasound, or during the operation.   
Results 
During the study period, 39 patients were diag-
nosed with Hürthle cell carcinoma. The majority of 
patients with HCC were women and the mean age at 
diagnosis of all patients was 58.7 years (Table 1). The 
preoperative diagnosis included 31 (79%) patients 
with Hürthle cell neoplasm, 3 (7%) with thyroid goi-
ter, 2 (5%) with HCC, 2 (5%) with follicular cell neop-
lasm and 1 (2%) with Graves’ disease. Four patients 
had risk factors for thyroid cancer; 1 had a family 
history of thyroid cancer, and 3 patients had a history 
of radiation exposure.  
 
Table 1: Characteristics of patients with Hürthle cell car-
cinoma 
Characteristics Values 
Total Patients 39 
Age (years), mean ± SD 58.7 ± 15.9 
Gender  
 Female, n (%) 23 (59)  
 Male, n (%) 16 (41) 
Race  
 Caucasian, n (%)  31 (79)  
 Asian, n (%) 4 (10) 
 African American, n (%) 1 (2) 
 Latino, n (%) 1 (2) 
 Other, n (%) 2 (5) 
Pathologic findings  
 Multifocal 7 (18) 
 Capsular invasion 17 (44) 
 Vascular invasion 23 (59) 
 Lymphatic invasion 5 (13) 
 Lymph node metastases 3(8) 
 
 
 
At the initial operation, 22 (56%) patients un-
derwent a thyroid lobectomy, 14 (36%) total thyroi-
dectomy, and 3 (8%) total thyroidectomy and lymph 
node dissection. Patients who underwent an initial 
thyroid lobectomy underwent a subsequent operation 
for a completion thyroidectomy. Of the 3 patients who 
received a lymph node dissection, 1 had ipsilateral 
central LN metastases identified intraoperatively and 
underwent a central LN dissection, and the other 2 
had lateral LN metastasis identified on preoperative 
ultrasound and underwent an ipsilateral central and 
lateral LN dissection.  
Though there was no gender difference between 
the two groups, patients with LN metastasis were 
older than those without (Figure 1: mean age 86.7 and 
56.4 years, respectively). Similarly, patients with LN 
metastasis had larger tumors than those without 
(Figure 2: mean size 6 and 4 cm, respectively). Tumor 
size was predictive of lymph node metastasis as no 
patient with tumor < 5cm presented with lymph node 
involvement (3/15 with >5cm cancer had node me-
tastasis, 0/24 with <5cm cancer had node metastasis).  
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Several histologic differences were evident be-
tween patients with and without lymph node metas-
tasis. All patients with lymph node metastasis had 
widely invasive tumors with capsular invasion, vas-
cular invasion and multifocal disease. Of the 36 tu-
mors without LN metastasis, 9 (25%) were mod-
erately-to-widely invasive, 14 (39%) had capsular in-
vasion, 20 (56%) had vascular invasion, and 4 (11%) 
were multifocal. Only extent of invasion and multi-
focality were associated with LN metastasis.  
 
 
Figure 1: Relationship between patient age and lymph node status in patients with Hürthle cell carcinoma 
 
 
 
 
Figure 2: Relationship between tumor size and lymph node status in patients with Hürthle cell carcinoma 
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Discussion 
 Our group previously showed that the overall 
rate of malignancy in FNA proven Hürthle cell neop-
lasms was 21% and that 55% of these tumors larger 
than 4cm were HCC. No single clinical factor can ac-
curately predict the malignant potential of Hürthle 
cell neoplasms. However, identifying such clinical 
factors can guide operative decision-making. For 
example, it has been suggested that a total thyroi-
dectomy, rather than a lobectomy, be considered for 
older patients with tumors larger than 4cm.8  
 In this series, we sought to determine if the size 
of the HCC tumor could predict the presence of LN 
metastasis. In our patient cohort, 8% of patients with 
HCC were found to have LN metastasis. This is simi-
lar to other reported rates of 3% to 13%.3, 9 Others, 
however, have report higher rates of 18% to 25%.10, 11 
Despite the associated risk of LN metastasis in pa-
tients with HCC, no studies have shown that HCC 
size predicts LN involvement.  
 This study demonstrates that HCC tumor size 
predicts LN metastasis. Patients who presented with 
LN metastasis had larger tumors than those who 
presented without LN metastasis. Interestingly, no 
patients with cancers < 5cm presented with LN me-
tastasis. On the other hand, 20% of patients with can-
cers > 5cm were found to have LN metastasis.  
 This study also demonstrates that all patients 
with LN metastasis had widely invasive and multi-
focal tumors. This finding has been corroborated in 
another study that demonstrated that all seven pa-
tients with LN metastasis had widely invasive HCC.9 
The presence of capsular invasion or vascular inva-
sion, however, did not predict LN involvement. 
Though HCC commonly affects women more often 
than men, gender was not an associated risk factor for 
developing LN metastasis.  
Older age is considered a risk factor for malig-
nancy in patients with Hürthle cell neoplasms.8 Simi-
larly, we found that advanced age was a risk for the 
presence of LN metastasis in patients with HCC. Spe-
cifically, all of our patients who presented with LN 
metastasis were octogenarians (Figure 1). This finding 
suggests that older patients with large HCC are at risk 
for developing lymph node metastasis. 
In summary, as size has been shown to predict 
the malignant potential of Hürthle cell neoplasms and 
this study demonstrate that size and age are also pre-
dictive of LN metastasis in patients with HCC. Our 
data suggest that consideration should be given to 
performing a prophylactic ipsilateral central neck 
dissection at the time of their initial operation in older 
patients with large tumors.  
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